GP120: target for neutralizing HIV-1 antibodies
- PMID: 16551265
- DOI: 10.1146/annurev.immunol.24.021605.090557
GP120: target for neutralizing HIV-1 antibodies
Abstract
The glycoprotein (gp) 120 subunit is an important part of the envelope spikes that decorate the surface of HIV-1 and a major target for neutralizing antibodies. However, immunization with recombinant gp120 does not elicit neutralizing antibodies against multiple HIV-1 isolates (broadly neutralizing antibodies), and gp120 failed to demonstrate vaccine efficacy in recent clinical trials. Ongoing crystallographic studies of gp120 molecules from HIV-1 and SIV increasingly reveal how conserved regions, which are the targets of broadly neutralizing antibodies, are concealed from immune recognition. Based on this structural insight and that from studies of antibody structures, a number of strategies are being pursued to design immunogens that can elicit broadly neutralizing antibodies to gp120. These include (a) the construction of mimics of the viral envelope spike and (b) the design of antigens specifically tailored to induce broadly neutralizing antibodies.
Similar articles
-
Importance of conformation on the neutralizing antibody response to HIV-1 gp120.Biotechnol Ther. 1991;2(1-2):63-89. Biotechnol Ther. 1991. PMID: 1726963
-
The antigenic structure of the HIV gp120 envelope glycoprotein.Nature. 1998 Jun 18;393(6686):705-11. doi: 10.1038/31514. Nature. 1998. PMID: 9641684
-
Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.J Virol. 2016 Nov 28;90(24):10993-11006. doi: 10.1128/JVI.01403-16. Print 2016 Dec 15. J Virol. 2016. PMID: 27630234 Free PMC article.
-
Challenges for structure-based HIV vaccine design.Curr Opin HIV AIDS. 2009 Sep;4(5):431-40. doi: 10.1097/COH.0b013e32832e6184. Curr Opin HIV AIDS. 2009. PMID: 20048708 Review.
-
Broadly neutralizing antibodies against HIV-1: templates for a vaccine.Virology. 2013 Jan 5;435(1):46-56. doi: 10.1016/j.virol.2012.10.004. Virology. 2013. PMID: 23217615 Review.
Cited by
-
A chloroplast-derived C4V3 polypeptide from the human immunodeficiency virus (HIV) is orally immunogenic in mice.Plant Mol Biol. 2012 Mar;78(4-5):337-49. doi: 10.1007/s11103-011-9870-1. Epub 2012 Jan 7. Plant Mol Biol. 2012. PMID: 22228408
-
Monoclonal antibodies to the V2 domain of MN-rgp120: fine mapping of epitopes and inhibition of α4β7 binding.PLoS One. 2012;7(6):e39045. doi: 10.1371/journal.pone.0039045. Epub 2012 Jun 13. PLoS One. 2012. PMID: 22720026 Free PMC article.
-
HIV-1 gp120 impairs the induction of B cell responses by TLR9-activated plasmacytoid dendritic cells.J Immunol. 2012 Dec 1;189(11):5257-65. doi: 10.4049/jimmunol.1201905. Epub 2012 Oct 24. J Immunol. 2012. PMID: 23100517 Free PMC article.
-
Association of enhanced HIV-1 neutralization by a single Y681H substitution in gp41 with increased gp120-CD4 interaction and macrophage infectivity.PLoS One. 2012;7(5):e37157. doi: 10.1371/journal.pone.0037157. Epub 2012 May 14. PLoS One. 2012. PMID: 22606344 Free PMC article.
-
Computational Refinement and Validation Protocol for Proteins with Large Variable Regions Applied to Model HIV Env Spike in CD4 and 17b Bound State.Structure. 2015 Jun 2;23(6):1138-49. doi: 10.1016/j.str.2015.03.026. Structure. 2015. PMID: 26039348 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
